0000000000327742

AUTHOR

Flavia Longo

showing 5 related works from this author

Corrigendum: Natural History of Non-Small-Cell Lung Cancer with Bone Metastases.

2016

We conducted a large, multicenter, retrospective survey aimed to explore the impact of tumor bone involvement in Non-Small Cell Lung Cancer.Data on clinical-pathology, skeletal outcomes and bone-directed therapies for 661 deceased patients with evidence of bone metastasis were collected and statistically analyzed. Bone metastases were evident at diagnosis in 57.5% of patients. In the remaining cases median time to bone metastases appearance was 9 months. Biphosphonates were administered in 59.6% of patients. Skeletal-related events were experienced by 57.7% of patients; the most common was the need for radiotherapy. Median time to first skeletal-related event was 6 months. Median survival a…

AdultAged 80 and overMaleLung NeoplasmsBone NeoplasmsMiddle AgedCorrigendaArticleYoung AdultCarcinoma Non-Small-Cell LungDisease ProgressionHumansFemaleAgedScientific reports
researchProduct

Treatment and outcome(s) of a large cohort of Italian patients (pts) with poor-risk metastatic renal cell carcinoma (prRCC)

2014

e15568 Background: With the exception of the Temsirolimus (Tem) registration trial, prRCC pts are grossly underrepresented in trials that have evaluated different therapeutic strategies. Methods: W...

OncologyCancer Researchmedicine.medical_specialtyPoor riskbusiness.industrymedicine.diseaseTemsirolimusLarge cohortSurgeryOncologyRenal cell carcinomaInternal medicinemedicinebusinessmedicine.drug
researchProduct

Natural History of Non-Small-Cell Lung Cancer with Bone Metastases

2015

AbstractWe conducted a large, multicenter, retrospective survey aimed to explore the impact of tumor bone involvement in Non-Small Cell Lung Cancer.Data on clinical-pathology, skeletal outcomes and bone-directed therapies for 661 deceased patients with evidence of bone metastasis were collected and statistically analyzed. Bone metastases were evident at diagnosis in 57.5% of patients. In the remaining cases median time to bone metastases appearance was 9 months. Biphosphonates were administered in 59.6% of patients. Skeletal-related events were experienced by 57.7% of patients; the most common was the need for radiotherapy. Median time to first skeletal-related event was 6 months. Median su…

OncologyAdultMalemedicine.medical_specialtyLung Neoplasmsmedicine.medical_treatmentECOG Performance StatusBone NeoplasmsYoung AdultInternal medicineCarcinomamedicine80 and overHumansYoung adultLung cancerNon-Small-Cell LungAgedLungMultidisciplinarybusiness.industryAdult Aged Aged 80 and over Bone Neoplasms Carcinoma Non-Small-Cell Lung Female Humans Lung Neoplasms Male Middle Aged Young Adult Disease Progression MultidisciplinaryCarcinomaBone metastasisMiddle Agedmedicine.diseaseRadiation therapymedicine.anatomical_structureConcomitantDisease ProgressionFemaleAdult; Aged; Aged 80 and over; Bone Neoplasms; Carcinoma Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Young Adult; Disease Progressionbusiness
researchProduct

Natural history of malignant bone disease in non-small cell lung cancer: Preliminary results of a multicenter bone metastasis survey

2013

e19084 Background: Bone metastases represent an increasing clinical problem in advanced non-small cell lung cancer (NSCLC) as disease-related survival improves. This is a multicenter, retrospective survey aimed to explore the impact of bone involvement in this severe, life-threatening disease. Methods: Data on clinicopathology, skeletal outcomes, skeletal-related events (SREs), and bone-directed therapies for 421 deceased NSCLC patients (48.6% aged >66 years) with evidence of bone metastasis were statistically analyzed. Results: ECOG performance status at diagnosis of NSCLC was 0 in 41.4% of patients, 1 in 42.8% and 2 in 13.9%. The most frequent stage at diagnosis was IV (76.8%). Adenoc…

OncologyCancer Researchmedicine.medical_specialtyPathologyBone diseasebusiness.industryBone metastasismedicine.diseaseNatural historyOncologyInternal medicinemedicineNon small cellLung cancerbusiness
researchProduct

A proposed new model for prognostic stratification of poor-risk patients with metastatic renal cell carcinoma (mRCC) in the era of targeted therapy.

2014

e15588 Background: The stratification of poor risk mRCC patients in the era of targeted therapy represents an unmet medical need. We analyzed, individually, each prognostic factor included in modif...

Cancer Researchmedicine.medical_specialtyPrognostic factorPoor riskbusiness.industrymedicine.medical_treatmenturologic and male genital diseasesmedicine.diseasePrognostic stratificationStratification (mathematics)Targeted therapyOncologyRenal cell carcinomaMedicinebusinessIntensive care medicine
researchProduct